Associations of NQO1 C609T and NQO1 C465T polymorphisms with acute leukemia risk: a PRISMA-compliant meta-analysis

Haiyong He¹
Xiaoyu Zhai¹,²
Xiaomin Liu³
Jie Zheng³
Yajing Zhai⁴
Fan Gao⁴
Yonghua Chen⁵
Jun Lu¹

¹Clinical Research Center, ²College of Pharmacy, Xi'an Jiaotong University, ³Dialysis Department of Nephrology Hospital, ⁴Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, ⁵School of Public Health, Xi'an Jiaotong University, Xi'an, China

Objective: The NAD(P)H:quinone oxidoreductase (NQO1) C609T and C465T polymorphisms have been widely thought to be associated with the risk of acute leukemia (AL) in recent years, but the correlations are still unclear. A meta-analysis is generally acknowledged as one of the best methods for secondary research, and so it was applied in this study with the aim of elucidating how the NQO1 C609T and C465T polymorphisms are related to the risk of AL.

Methods: Relevant studies were searched in the PubMed, EMBASE, CNKI, and Wanfang databases, and the obtained data were analyzed using Stata (version 12.1). The allele-contrast model was applied, and odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate relationship strengths. Meta-regression was used to identify sources of heterogeneity, and subgroup analyses were conducted. Publication bias was analyzed using funnel plots, with the trim-and-fill method used to analyze the effect of publication bias on pooled results. In addition, sensitivity analysis, the fail-safe number method, and cumulative analysis by publication year were performed to measure the stability of the obtained results.

Results: This meta-analysis included 28 relevant studies involving 5,953 patients and 8,667 controls. Overall, the C609T polymorphism was associated with the risk of acute lymphoblastic leukemia (ALL; OR=1.18, 95% CI=1.00–1.39, p=0.05). Meanwhile, race was found to be a potential source of heterogeneity for the relationship between the C609T polymorphism and acute myeloid leukemia (AML) risk, and the subgroup analysis identified the C609T polymorphism as a risk factor for AML in Asians (OR=1.34, 95% CI=1.03–1.74, p=0.03). The number of studies about C465T polymorphism was too small to pool the data.

Conclusion: There are increased risks of ALL in all subjects and of AML in Asians for carriers of the NQO1 C609T polymorphism. Further studies are needed to verify the associations of the C465T polymorphism with the risk of AL.

Keywords: NQO1, polymorphism, AML, ALL

Introduction

Leukemia is a clonal disorder of hematopoietic cells that is mostly associated with genetic mutation along with a diversity of chromosomal and molecular changes.¹ It is one of top ten malignant tumors in China, and the number of leukemia patients has increased markedly in recent years.² Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are the most common types of acute leukemia (AL) in both adults and children. Although there are well-documented studies of the clinical and biological aspects of leukemia, little is known about the predisposing factors of leukemia.³ Smoking, obesity, and exposure to radiation and chemical carcinogens are putative or actual risk factors for AL. However, AL only develops in a small proportion
of individuals who have been exposed to these environmental and lifestyle risk factors, and so the genetic background may also be a possible etiology in AL.\textsuperscript{4}

NAD(P)H:quinone oxidoreductase (NQO1), which was originally called DT-diaphorase, is a flavoenzyme that can detoxify quinones derived from the oxidation of phenolic metabolites of benzene by catalyzing two or four electron reductions of these substrates. It can protect cells against oxidative damage by preventing redox cycling and the generation of free radicals.\textsuperscript{5} Single-nucleotide polymorphisms (SNPs) are the most common type of variant in the human genome.\textsuperscript{6} A widely researched SNP in NQO1 is C609T. A C/T change at nucleotide 609 causes a proline-to-serine substitution and therefore destabilizes and inactivates the enzyme. Individuals with TT genotype completely lack NQO1 activity, and CT genotype carriers present about threefold decreased enzyme activity compared with wild-type carriers.\textsuperscript{7} The frequency of the NQO1 C609T polymorphism exhibits ethnic variation. The prevalence of the homozygous variant genotype (TT) was ~20\% in Asian populations and 4\% in Caucasians.\textsuperscript{8} Another common SNP was C465T: a C/T change at nucleotide 465. This SNP can also diminish the activity of NQO1.\textsuperscript{9} So the ability to detoxify carcinogens is reduced when these two polymorphisms are present, which may increase the probability of malignant changes in susceptible individuals.\textsuperscript{10} These observations support the hypothesis that the TT genotypes for C609T or C465T polymorphisms are likely to be related to the high risk of AL.

It is possibly more meaningful to analyze the effects of genotype–environment interactions on chronic leukemia, and the genetic background may play a more important role in the etiology of AL. Since 2000, the NQO1 C609T and NQO1 C465T polymorphisms have been widely thought to be associated with the risk of AL, but the correlations are still unclear, possibly due to insufficient studies with complete data, diverse study designs and methods, differences in race and geography, and publication bias.

A meta-analysis of published case–control studies was therefore undertaken to precisely evaluate whether the NQO1 C609T and NQO1 C465T polymorphisms are associated with the risk of AL. Potential sources of heterogeneity, subgroups, stability of results, and publication bias were carefully analyzed in this study.

Methods
This meta-analysis was designed and written according to the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-analyses.

Search strategy
The medical literature on associations between the AL risk and the NQO1 C609T and NQO1 C465T polymorphisms that was published before February 2016 was searched in the PubMed, EMBASE, CNKI, and Wanfang electronic databases. The following combination of keywords was used: [AL OR (acute leukemia) OR (AML) OR (acute myeloid leukemia) OR (acute myelocytic leukemia) OR (acute myeloblastic leukemia) OR (ALL) OR (acute lymphocytic leukemia) OR (acute lymphoblastic leukemia)] AND [NQO1 OR (quinone reductase 1) OR (quinone oxidoreductase 1)] AND [polymorphism OR allele OR variant OR variation OR genotype]. The research subjects were limited to humans, and the language was limited to English or Chinese. The references in identified publications were also browsed in order to identify any other relevant studies.

Eligibility criteria
The following inclusion criteria were applied to the studies: 1) must focus on associations of the NQO1 C609T and NQO1 C465T polymorphisms with the AL risk; 2) must have a case–control design; and 3) the reported genotype distribution data must be sufficient to allow the odds ratios (ORs) with 95\% confidence intervals (CIs) to be calculated. Studies involving larger samples or published more recently were selected in cases of repeated studies or overlapping data. If the reported data were incomplete, the corresponding author was contacted to obtain complete data.

Data extraction
The following details were extracted from all eligible studies: first author, publication year, race of included subjects, sample sizes of cases and controls, age group, genotyping method, source of controls, mutational location in NQO1, sample sizes of cases and controls, age group, genotyping method, source of controls, mutational location in NQO1, quality score, and results of the Hardy–Weinberg equilibrium (HWE) test for the controls.

Quality assessment
The quality of the included studies was assessed using the quality scoring criteria employed in a previous meta-analysis.\textsuperscript{11} The representativeness of cases, source of controls, genotyping examination (whether or not genotyping was performed under a blinded condition), the association assessment method, and the HWE test for controls were included as quality assessment indicators. The quality score was calculated by summing the scores for all of these indicators, with the total score ranging from 0 to 10 points. Studies with a score of <6 points were considered to be of low quality.
Statistical analysis

An allele-contrast model was used to investigate the associations of the NQO1 C609T and NQO1 C465T polymorphisms with the risk of AL, and relationship strengths were assessed by ORs with 95% CIs. The statistical random-effects model was used to evaluate different underlying influences and consider variations within or among studies, which provided the advantages of accommodating diversity among studies and offering more conservative evaluations.

Heterogeneity among the studies was analyzed by the chi-square test based on the Q statistic, with significant heterogeneity considered to be present when the P-value was $< 0.1$. The heterogeneity was quantified by the I² value, with a value $> 50\%$ indicating higher heterogeneity among the studies. The potential sources of heterogeneity were explored by meta-regression based on the following covariates: race, age, and source of controls. A subgroup analysis was also performed using these covariates.

The publication bias was analyzed by using funnel plots, where an asymmetric funnel plot indicates the presence of such bias. The symmetry of a funnel plot was quantified using Egger’s linear regression test, where a P-value of $< 0.05$ was considered to indicate significant asymmetry and significant publication bias existence. Then the trim-and-fill method was used to assess the effect of publication bias on pooled results.

A cumulative analysis by publication year was performed to observe the trend of pooled results over time. The influence analysis of single study was applied to assess the robustness of the obtained results. Meanwhile, sensitivity analyses were also applied to studies of low quality or that did not conform to HWE to evaluate the effect of these studies on the overall results. In addition, the fail-safe number of negative studies that would be required to nullify (ie, make $P > 0.05$) the effect size was calculated, and a bigger number indicated a more stable pooled result. Stata (version 12.1) was used for all of the statistical tests.

Results

Study characteristics

In total, 893 articles were searched in electronic databases, which resulted in the inclusion of 28 studies. Among the articles, 18 and 18 were about the associations of the NQO1 C609T polymorphism with the risks of AML and ALL, respectively, two were about the association between the NQO1 C465T polymorphism and the AML risk, and three were about the association between the NQO1 C465T polymorphism and the ALL risk. Among these studies, 11 focused on Caucasians, $1,3,12–20$ 10 on Asians $2,9,10,21–27$ four on mixed populations $5,28–30$ two on Africans $31,32$ and one on Javanese $33$. In terms of the genotype distribution of controls, 20 of the studies about the association between the NQO1 C609T polymorphism and the ALL risk conformed with HWE $1,3,5,9,12–14,20,22–24,28,30–33$ while seven did not $1,2,10,21,25–27,29$ and the HWE test could not be applied to one study $13$ because of insufficient data. Two studies of the association between the NQO1 C465T polymorphism and the ALL risk conformed with HWE $16,19$ while two did not $23,24$. Moreover, there were two studies of low quality $2,13$. A flow diagram of the study selection procedure is shown in Figure 1, and the main characteristics of the included studies are presented in Table 1.

NQO1 C609T polymorphism and the ALL risk

Eighteen relevant studies were used to assess the association between the NQO1 C609T polymorphism and the ALL risk. The pooled result revealed a marginally increased risk of ALL for the NQO1 C609T polymorphism (OR $1.18, 95\%$ CI $=1.00–1.39$, $P=0.05$; Figure 2A). The fail-safe number was 77.03. The heterogeneity was high ($I^2=73.0\%$), but meta-regression did not reveal the potential source of this heterogeneity. In addition, an increased ALL risk for adults was found in the subgroup analysis (OR $1.71, 95\%$ CI $=1.20–2.43$, $P=0.003$). The results of the subgroup analysis are presented in Table 2.

When attempting to identify the presence of publication bias, it is difficult to assess whether a funnel plot is symmetric merely by visual examination. Egger’s linear regression test provided evidence of asymmetry ($P=0.031$). The publication bias was adjusted by the trim-and-fill method; after that, the pooled result did not change (ie, the effect size from 1.322, 95% CI $=1.091–1.554$, to 3.752, 95% CI $=2.977–4.730$; Figure 2D), meaning that the analyses were stable, and moreover that future new research might not change the pooled results. In addition, the influence analysis of single study showed that the total pooled result was greatly affected by the 15 studies (Figure 2B) $2,3,9,10,12,13,15,16,19,21,25,26–31$. Excluding any of these studies resulted in the statistically significant loss of pooled OR values. Meanwhile, the sensitivity analysis revealed that deleting two studies of low quality $2,13$ five studies that did not conform to HWE $2,10,21,25,29$ or one study for which the HWE test was not applied did not change the pooled ORs $13$, showing that these factors did not affect the stability of the pooled results. No stable tendency was found in the cumulative analysis by publication year (Figure 2C).
**NQO1 C609T polymorphism and the AML risk**

Eighteen relevant studies were used to assess the association between the NQO1 C609T polymorphism and the AML risk. The pooled result was not statistically significant (OR = 1.11, 95% CI = 0.94–1.30, P = 0.23; Figure 3A). The heterogeneity was high (I^2 = 71.5%), and meta-regression revealed that race and the source of controls were potential sources of this heterogeneity. In addition, an increased AML risk for Asians, adults, and hospital-based control groups was found in the subgroup analysis. The results of the subgroup analysis are presented in Table 2. Egger’s linear regression test provided evidence of symmetry (P = 0.338, Figure 3B).

**NQO1 C465T polymorphism and risks of AML and ALL**

Three relevant studies assessed the association between the NQO1 C465T polymorphism and the ALL risk, of which two did not find a significant association^9,16 and one found an increased risk of ALL for the NQO1 C465T polymorphism. Two relevant studies researched the association between the NQO1 C465T polymorphism and the AML risk, and both of them did not find a significant association.9,23

**Discussion**

The method of meta-analysis was used in this study to integrate the published evidence on the associations of the NQO1 C609T and NQO1 C465T polymorphisms with the risk of AL. A heterogeneity evaluation, source searching, sensitivity analysis, publication bias analysis, and analysis of the stability of results were also conducted.

The NQO1 C609T polymorphism was found to be a risk factor for ALL. However, the P-value was only marginally significant, which may have been related to the sample size, and so a more precise result will need to be obtained in the future by using a larger sample. This polymorphism was associated with an increased ALL risk for adults. The different results for children and adults may have been due to the AL etiology differing between these two populations.34 Children are generally more susceptible to environmental toxins because of their immature metabolism and their faster cell division and growth compared with adults.35 This result
also suggests the presence of age stratification for the AL risk, and so age-stratification studies are needed to clarify this. Moreover, this research result was very sensitive, which may be due to the number of raw studies being too small, and so more relevant studies are needed to verify the association between the NQO1 C609T polymorphism and the ALL risk in the future.

The association between the NQO1 C609T polymorphism and the ALL risk was analyzed by Li and Zhou in four models. They found that this polymorphism increased the ALL risk in a recessive model and a model of T/T versus C/C, while no statistical significance was seen in a dominant model or a model of C/T versus C/C. Their subgroup analysis found that the NQO1 C609T polymorphism increased the ALL risk for adults in a dominant model and a model of T/T versus C/C. The allele-comparison model was used in this study, and it was found that the NQO1 C609T polymorphism increased the ALL risk, with the effect size of an increased ALL risk for adults still being significant in the subgroup analysis. Only the allele-contrast model was selected for this

### Table 1 Characteristics of included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Ethnicity</th>
<th>Sample size</th>
<th>Age</th>
<th>Genotyping method</th>
<th>Control sources</th>
<th>Polymorphism of NQO1</th>
<th>Cases</th>
<th>P-value for HWE</th>
<th>Quality score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bolufer et al</td>
<td>2007</td>
<td>Caucasian</td>
<td>302/141</td>
<td>Adult/Children</td>
<td>PCR-based methods</td>
<td>PB/Imputation</td>
<td>C609T</td>
<td>454/454</td>
<td>AML</td>
<td>0.422</td>
</tr>
<tr>
<td>Bonaventure et al</td>
<td>2012</td>
<td>Caucasian</td>
<td>433/51</td>
<td>Children</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>441</td>
<td>AML</td>
<td>0.205</td>
</tr>
<tr>
<td>Chan et al</td>
<td>2011</td>
<td>Javanese</td>
<td>185/15</td>
<td>Children</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>177</td>
<td>AML</td>
<td>0.926</td>
</tr>
<tr>
<td>Clavel et al</td>
<td>2005</td>
<td>Mixed</td>
<td>219/51</td>
<td>Children</td>
<td>PCR-RFLP</td>
<td>HB</td>
<td>C609T</td>
<td>105</td>
<td>AML</td>
<td>0.673</td>
</tr>
<tr>
<td>de Aguiar et al</td>
<td>2012</td>
<td>Mixed</td>
<td>519/107</td>
<td>Children</td>
<td>PCR</td>
<td>PB</td>
<td>C609T</td>
<td>401</td>
<td>AML</td>
<td>0.057</td>
</tr>
<tr>
<td>Goncalves et al</td>
<td>2005</td>
<td>Asian</td>
<td>103/103</td>
<td>Children</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>185</td>
<td>ALL</td>
<td>0.482</td>
</tr>
<tr>
<td>Eguchi-Ishimae et al</td>
<td>2007</td>
<td>Caucasian</td>
<td>19/13</td>
<td>NA</td>
<td>PCR-RFLP</td>
<td>NA</td>
<td>C609T</td>
<td>11</td>
<td>AML</td>
<td>3</td>
</tr>
<tr>
<td>Eyada et al</td>
<td>2007</td>
<td>Caucasian</td>
<td>81/48</td>
<td>Adult</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>64</td>
<td>AML</td>
<td>0.556</td>
</tr>
<tr>
<td>Gilleum et al</td>
<td>2012</td>
<td>Asian</td>
<td>102/48</td>
<td>Adult</td>
<td>LDR</td>
<td>HB</td>
<td>C609T</td>
<td>150</td>
<td>AML</td>
<td>0.005</td>
</tr>
<tr>
<td>Jia et al</td>
<td>2004</td>
<td>Caucasian</td>
<td>138/138</td>
<td>Adult</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>190</td>
<td>AML</td>
<td>0.218</td>
</tr>
<tr>
<td>Krauch et al</td>
<td>2002</td>
<td>Caucasian</td>
<td>174/48</td>
<td>Adult</td>
<td>PCR</td>
<td>PB</td>
<td>C609T</td>
<td>323</td>
<td>ALL</td>
<td>0.147</td>
</tr>
<tr>
<td>Krajinovic et al</td>
<td>2006</td>
<td>Mixed</td>
<td>262/102</td>
<td>Adult</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>688</td>
<td>AML</td>
<td>0.295</td>
</tr>
<tr>
<td>Malik et al</td>
<td>2000</td>
<td>Asian</td>
<td>41/41</td>
<td>Adult</td>
<td>PCR</td>
<td>PB</td>
<td>C609T</td>
<td>150</td>
<td>AML</td>
<td>0.037</td>
</tr>
<tr>
<td>Naoe et al</td>
<td>2000</td>
<td>Asian</td>
<td>100/100</td>
<td>Adult</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>106</td>
<td>AML</td>
<td>0.155</td>
</tr>
<tr>
<td>Ouwerhui et al</td>
<td>2013</td>
<td>African</td>
<td>60/60</td>
<td>Children</td>
<td>PCR-CTPP</td>
<td>PB</td>
<td>C609T</td>
<td>60</td>
<td>AML</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Remando et al</td>
<td>2010</td>
<td>Caucasian</td>
<td>168/168</td>
<td>Adult</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>178</td>
<td>AML</td>
<td>0.12</td>
</tr>
<tr>
<td>Silvera Vda et al</td>
<td>2009</td>
<td>Caucasian</td>
<td>206/206</td>
<td>Children</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>364</td>
<td>AML</td>
<td>0.218</td>
</tr>
<tr>
<td>Sinem et al</td>
<td>2004</td>
<td>Mixed</td>
<td>189/84</td>
<td>Children</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>286</td>
<td>AML</td>
<td>0.016</td>
</tr>
<tr>
<td>Sorour et al</td>
<td>2013</td>
<td>African</td>
<td>90/84</td>
<td>Adult</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>60</td>
<td>AML</td>
<td>0.299</td>
</tr>
<tr>
<td>Voso et al</td>
<td>2007</td>
<td>Caucasian</td>
<td>160/160</td>
<td>Adult</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>162</td>
<td>AML</td>
<td>0.12</td>
</tr>
<tr>
<td>Yamaguti et al</td>
<td>2009</td>
<td>Caucasian</td>
<td>133/99</td>
<td>Children</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>133</td>
<td>AML</td>
<td>0.054</td>
</tr>
<tr>
<td>Yamaguti et al</td>
<td>2010</td>
<td>Caucasian</td>
<td>99/99</td>
<td>Children</td>
<td>PCR</td>
<td>PB</td>
<td>C609T</td>
<td>99</td>
<td>AML</td>
<td>0.133</td>
</tr>
<tr>
<td>Yang et al</td>
<td>2005</td>
<td>Asian</td>
<td>228/228</td>
<td>Adult</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>241</td>
<td>AML</td>
<td>0.495</td>
</tr>
<tr>
<td>Zaker et al</td>
<td>2011</td>
<td>Asian</td>
<td>140/140</td>
<td>Adult</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>160</td>
<td>AML</td>
<td>0.19</td>
</tr>
<tr>
<td>Zaker et al</td>
<td>2012</td>
<td>Asian</td>
<td>100/100</td>
<td>Children</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>135</td>
<td>AML</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Zhang et al</td>
<td>2009</td>
<td>Asian</td>
<td>170/170</td>
<td>Adult</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>458</td>
<td>AML</td>
<td>0.162</td>
</tr>
<tr>
<td>Xu</td>
<td>2010</td>
<td>Asian</td>
<td>78/78</td>
<td>Adult</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>100</td>
<td>AML</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Yang</td>
<td>2006</td>
<td>Asian</td>
<td>306/22</td>
<td>Adult</td>
<td>PCR-RFLP</td>
<td>PB</td>
<td>C609T</td>
<td>458</td>
<td>AML</td>
<td>0.017</td>
</tr>
</tbody>
</table>

Abbreviations: AL, acute leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; HWE, Hardy–Weinberg equilibrium; NQO1, NAD(P)H-quinone oxidoreductase; NA, not available; HB, hospital-based; PB, population-based; PCR, polymerase chain reaction; PCR-CPP, PCR confronting two-pair primer; LDR, ligase detection reaction; RFLP, restriction fragment length polymorphism.

OncoTargets and Therapy 2017:10

submit your manuscript | www.dovepress.com

Dovepress

1797

For personal use only. This work is licensed under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).

Dovepress

OncoTargets and Therapy 2017:10

submit your manuscript | www.dovepress.com

Dovepress

1797

For personal use only. This work is licensed under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).
**Figure 2** The associations between NQO1 C609T and the ALL risk. (A) Calculated ORs and 95% CIs for the association. (B) Sensitivity analysis via deletion of each individual study. (C) Cumulative meta-analysis according to publication year. (D) Trim-and-fill plot to correct publication bias.

**Note:** Weights are from random-effects analysis.

**Abbreviations:** NQO1, NAD(P)H:quinone oxidoreductase; ALL, acute lymphoblastic leukemia; OR, odds ratio; CI, confidence interval.
meta-analysis, which could avoid the reuse of data and thus reduce false positive results.

No statistically significant results were found for AML in this study. Meta-regression revealed race to be a potential source of heterogeneity. The subgroup analysis showed that the NQO1 C609T polymorphism is a risk factor for AML in Asians. The meta-analysis showed that the NQO1 C609T polymorphism is a risk factor for bladder and bowel cancer in Caucasians, but a protective factor in Asians; these differences indicate that genetic mechanisms may differ between Asians and Caucasians. In addition, the NQO1 C609T polymorphism was a risk factor for AML when the controls were from hospitals, but there were only two raw studies involving hospital-based controls, which suggests that caution is required when interpreting this result owing to the small number of samples and the corresponding low statistical power.

The association between the NQO1 C609T polymorphism and the AML risk was analyzed by Li et al in four models. They found that the NQO1 C609T polymorphism increased the AML risk using the recessive fixed-effects model and the model of TT versus CC. However, no statistical significance was seen in the dominant random-effects model or the model of CT versus CC. In addition, the NQO1 C609T polymorphism increased the risks of AML in adults and Asians in the subgroup analysis in the recessive random-effects model in their study. In this study, no statistically significant association was found between this SNP and the AML risk under the allele-comparison model, but significant associations were found for Asians, adults, and hospital-based control groups, which was consistent with the study by Li et al. The main differences between this study and the two articles by Li et al. were mainly reflected in the following two aspects: 1) this sample was larger because several raw studies were newly added and 2) the stability of pooled results was also analyzed to provide a more objective evaluation.

Only a small amount of the literature focuses on the relationships of the NQO1 C465T polymorphism with the risks of ALL and AML, which was definitely not enough to interpret this result owing to the small number of samples and the corresponding low statistical power.

The association between the NQO1 C609T polymorphism and the AML risk was analyzed by Li et al in four models. They found that the NQO1 C609T polymorphism increased the AML risk using the recessive fixed-effects model and the model of TT versus CC. However, no statistical significance was seen in the dominant random-effects model or the model of CT versus CC. In addition, the NQO1 C609T polymorphism increased the risks of AML in adults and Asians in the subgroup analysis in the recessive random-effects model in their study. In this study, no statistically significant association was found between this SNP and the AML risk under the allele-comparison model, but significant associations

Table 2 Subgroup analysis for the association of NQO1 C609T with AL risk

<table>
<thead>
<tr>
<th>Association</th>
<th>Factors</th>
<th>Subgroups</th>
<th>N</th>
<th>OR</th>
<th>95% CI</th>
<th>P-value*</th>
<th>I² (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C609T and ALL</td>
<td>Ethnicity</td>
<td>Caucasians</td>
<td>6</td>
<td>1.20</td>
<td>0.94–1.53</td>
<td>0.005</td>
<td>70</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Asians</td>
<td>6</td>
<td>1.25</td>
<td>0.78–2.00</td>
<td>&lt;0.0001</td>
<td>86</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mix</td>
<td>3</td>
<td>0.98</td>
<td>0.79–1.22</td>
<td>0.12</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Javanese</td>
<td>1</td>
<td>1.16</td>
<td>0.85–1.56</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>African</td>
<td>1</td>
<td>1.57</td>
<td>1.01–2.44</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Age</td>
<td>Children</td>
<td>12</td>
<td>1.03</td>
<td>0.87–1.22</td>
<td>0.001</td>
<td>64</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adult</td>
<td>5</td>
<td>1.71</td>
<td>1.20–2.43</td>
<td>0.003</td>
<td>75</td>
</tr>
<tr>
<td></td>
<td>Control source</td>
<td>PB</td>
<td>13</td>
<td>1.12</td>
<td>0.96–1.30</td>
<td>0.001</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HB</td>
<td>4</td>
<td>1.59</td>
<td>0.83–3.05</td>
<td>&lt;0.0001</td>
<td>89</td>
</tr>
<tr>
<td>C609T and AML</td>
<td>Ethnicity</td>
<td>Caucasians</td>
<td>7</td>
<td>1.02</td>
<td>0.83–1.26</td>
<td>0.14</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Asians</td>
<td>7</td>
<td>1.34</td>
<td>1.03–1.74</td>
<td>0.0002</td>
<td>77</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mix</td>
<td>3</td>
<td>0.83</td>
<td>0.58–1.19</td>
<td>0.05</td>
<td>66</td>
</tr>
<tr>
<td></td>
<td></td>
<td>African</td>
<td>1</td>
<td>1.06</td>
<td>0.58–1.94</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Age</td>
<td>Children</td>
<td>4</td>
<td>0.80</td>
<td>0.63–1.01</td>
<td>0.4</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adult</td>
<td>13</td>
<td>1.19</td>
<td>1.00–1.42</td>
<td>&lt;0.0001</td>
<td>72</td>
</tr>
<tr>
<td></td>
<td>Control source</td>
<td>PB</td>
<td>15</td>
<td>1.03</td>
<td>0.88–1.21</td>
<td>&lt;0.0001</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HB</td>
<td>2</td>
<td>1.92</td>
<td>1.45–2.55</td>
<td>0.81</td>
<td>0</td>
</tr>
</tbody>
</table>

Note: *P-value for heterogeneity test.

Abbreviations: AL, acute leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CI, confidence interval; N, numbers of comparisons; NA, not available; NQO1, NAD(P)H:quinone oxidoreductase; OR, odds ratio; HB, hospital-based; PB, population-based; NA, not available.

Conclusion

The NQO1 C609T polymorphism may be associated with an increased risk of AL. T allele carriers might be more
susceptible to AL and thus should pay more attention to away from environmental and lifestyle risk factors. In order to provide better guidance for clinical practice, future studies need to verify the relationships of the NQO1 C609T polymorphism with the risks of ALL and AML.

Acknowledgments
This work was supported by the Natural Science Foundation of Shaanxi Province (number 2015JM8415) and the Fundamental Research Funds for the Central Universities of China (number 2011jdhz55).

Disclosure
The authors report no conflicts of interest in this work.

References
17. Silveira Vda S, Canalle R, Scrideli CA, Queiroz RG, Tone LG. Role
16. Krajinovic M, Sinnett H, Richer C, Labuda D, Sinnett D. Role of NQO1,
15. Kracht T, Schrappe M, Strehl S, et al. NQO1 C609T polymorphism in
“de novo” acute myeloid leukaemia in individuals with cytochrome
28. de Aguiar Goncalves BA, Vasconcelos GM, Thuler LC, et al. NQO1
6. Yuan L, Zhang TT, Ren Y. miR-27a rs985189 polymorphism and risk of
22. Yang L, Zhang Y, Zhang MR, Xiao ZJ. Relationship between GSTT1,
GSTM1 and NQO1 gene polymorphism and acute myeloid leukemia and
recurrent chromosome translocations. Zhonghua Yi Xue Za Zhi.
23. Zaker F, Safaei A, Hashemi M, Pazzakh V. The frequency and asso-
ciation of C609T and C465T polymorphisms of NAD(P)H:quinone
24. Zaker F, Safaei A, Nasiri N, Abdollahzadeh M, Pazzakh V. The asso-
ciation of NAD(P)H:quinone oxidoreductase gene polymorphisms
256–261.
RAD51(G135C), XRCC3(C241T) single nucleotide polymorphisms and
26. de Aguiar Goncalves BA, Vasconcelos GM, Thuler LC, et al. NQO1
rs1800566 (C609T), PON1 rs662 (Q192R), and PON1 rs854560 (L55M)
polymorphisms segregate the risk of childhood acute leukemias accord-
ing to age range distribution. Cancer Causes Control. 2012;23(11):
1811–1819.
27. Yang L, Zhang Y, Zhang MR, Xiao ZJ. Relationship between GSTT1,
GSTM1 and NQO1 gene polymorphism and acute myeloid leukemia and
recurrent chromosome translocations. Zhonghua Yi Xue Za Zhi.
28. de Aguiar Goncalves BA, Vasconcelos GM, Thuler LC, et al. NQO1
rs1800566 (C609T), PON1 rs662 (Q192R), and PON1 rs854560 (L55M)
polymorphisms segregate the risk of childhood acute leukemias accord-
ing to age range distribution. Cancer Causes Control. 2012;23(11):
1811–1819.
1 null genotype is not associated with pediatric de novo acute leukemia.
30. Clavel J, Bellec S, Rebouissou S, et al. Childhood leukaemia, polymor-
phisms of metabolism enzyme genes, and interactions with maternal
tobacco, coffee and alcohol consumption during pregnancy. Eur J
31. Ouerhani S, Cherif N, Bahri I, Safra I, Menif S, Abbes S. Genetic poly-
morphisms of NQO1, CYP1A1 and TPMT and susceptibility to acute
40(2):1307–1314.
32. Sorour A, Ayad MW, Kassem H. The genotype distribution of the
XRCC1, XRCC3, and XPD DNA repair genes and their role for the
development of acute myeloblastic leukemia. Genet Test Mol
33.Chan JYS, Ugrasena DG, Lum DWK, Lu Y, Yeoh AEJ. Xenobiotic and
folate pathway gene polymorphisms and risk of childhood acute lympho-
blastic leukaemia in Javanese children. Hematol Oncol. 2011;29(3):
116–123.
34. Larfors G, Hallböök H, Simonsson B. Parental age, family size, and
offspring’s risk of childhood and adult acute leukemia. Cancer Epidemiol
35. Perera FP. Environment and cancer: who are susceptible?
36. Li C, Zhou Y. Association between NQO1 C609T polymorphism and
acute lymphoblastic leukemia risk: evidence from an updated meta-anal-
ysis based on 17 case-control studies. J Cancer Res Clin Oncol.